Log In
Print
BCIQ
Print
Print this Print this
 

STX107

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionMetabotropic glutamate receptor subtype 5 (mGluR5) antagonist
Molecular Target Metabotropic glutamate receptor subtype 5 (mGluR5) (GRM5)
Mechanism of ActionMetabotropic glutamate receptor subtype 5 (mGluR5) antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationFragile X syndrome
Indication DetailsTreat fragile X syndrome
Regulatory Designation

Partner

Seaside Therapeutics Inc.


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today